Most Favored Nation Drug Pricing Proposal Threatens Patient Access and Pharmaceutical Innovation, Experts Warn
Key Insights
The Trump administration's proposed Most Favored Nation (MFN) policy would tie U.S. drug prices to the lowest prices set by foreign governments, raising concerns among patient advocates and policy experts.
A University of Chicago analysis estimates MFN-style controls could cut U.S. research spending in half, resulting in approximately 500 fewer new medicines over the next decade.
Americans currently have access to 88% of newly launched medicines worldwide, compared to just 36% in 19 other high-income countries and 43% in Japan.
The Trump administration's push to tie U.S. drug prices to those set by foreign governments through a Most Favored Nation (MFN) policy has drawn sharp criticism from patient advocates and policy experts, who warn the approach could severely curtail American patients' access to medicines and stifle pharmaceutical innovation globally.
Andrew Spiegel, executive director of the Global Colon Cancer Association (search), argues that while the president is correct that other wealthy nations have long benefited from American pharmaceutical innovation without paying their fair share, the proposed MFN solution would move the United States in "exactly the wrong direction."
"Rather than forcing foreign governments to contribute more to innovation, MFN would effectively import their price controls by pegging U.S. drug prices to the lowest prices abroad," Spiegel wrote in a piece originally published in the Washington Examiner.
The Cost of Innovation
Bringing a new drug to market requires an average investment of nearly $2.7 billion, according to Spiegel. Yet governments in Europe, Japan, and elsewhere routinely impose price controls on medicines, paying a fraction of what Americans do. These foreign governments achieve lower prices by delaying access and devaluing medicines in ways that Spiegel says Americans "roundly reject."
The economic consequences of MFN could be severe. A University of Chicago analysis estimated that MFN-style controls could cut U.S. research spending in half, resulting in roughly 500 fewer new medicines over the next decade. "The consequences of stifled innovation would be felt by patients in the United States — and by patients across the globe," Spiegel noted.
Disparities in Patient Access
The access gap between the United States and other developed nations is stark. In a study of 19 high-income countries, patients have access to just 36% of the newest medicines, while Americans have access to 88% of them. Japan, a country that bears a heavy burden from colorectal cancer (search), provides particularly troubling data: Japanese patients gained access to just 43% of newly launched medicines worldwide in recent years, compared to more than 80% for Americans.
Spiegel attributes this disparity to Japan's system of "mandatory, across-the-board price cuts" that has severely constrained patient access. European countries including the United Kingdom, France, and Italy rely on standardized health technology assessments that "routinely undervalue cutting-edge therapies — particularly for older adults and people with chronic illnesses, whose lower baseline health often makes treatment appear less 'cost-effective.'"
Broader Implications for Florida and Beyond
Stacy Snow Feiler, former president of Liberty Tree Consulting (search), highlighted the particular risks MFN policies pose to states like Florida, with its large population of retirees and individuals with chronic conditions. "MFN drug pricing threatens to stifle innovation in the pharmaceutical sector, which is crucial to developing new treatments for conditions that affect many Floridians," Feiler wrote.
Feiler also warned that MFN policies could lead to drug shortages, as manufacturers might choose to allocate products to countries where they can charge higher prices. "This alarming scenario would disproportionately affect low-income families, the elderly, and those living in rural areas with limited access to healthcare," she stated.
The policy could also create a "chilling effect on competition," Feiler argued, by standardizing prices and eliminating incentives for drug manufacturers to compete on cost or invest in innovative treatment options.
An Alternative Path Forward
Rather than importing foreign price controls, Spiegel advocates for a Section 301 investigation into foreign governments' unfair pharmaceutical pricing practices. Such an approach, he contends, "would give the United States meaningful leverage to pressure other wealthy nations to stop freeloading off American innovation."
"The credible threat of trade consequences could force long-overdue reforms in countries that systematically undervalue new medicines," Spiegel wrote. "The greatest threat to patients is a world in which the lifesaving medicines they are counting on are never developed. MFN would move us closer to that world. And patients everywhere would pay the price."